HomeToday’s HighlightsAmgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Today’s Highlights April 10, 2019 Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Amgen (AMGN), UCB Pharmaceuticals (UCB) April 10, 2019 Tweet Pin It Other Articles PTC Therapeutics: U.S. FDA Approved a First-Time Gene Therapy Administered directly into the Brain to Treat Children and Adults November 14, 2024 0 BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million November 12, 2024 0 Intellia Therapeutics: Positive Results from NTLA-2002 in CRISPR Gene Editing Treatment for Hereditary Angioedema October 25, 2024 0 Vertex Pharmaceuticals to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the ASA Annual Meeting. October 18, 2024 0